IONS stock news

IONS stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-23 17:43:00 UTC#508247duplicateconfirmednews

Ionis and Roche report sefaxersen met primary endpoint with 43.1% proteinuria reduction in Phase 3 IgAN study

tradingviewimportance 0.40trust 0.70Ionis Pharmaceuticals, Inc. +0.60Roche Holding AG +0.60sefaxersen +0.60+1 entities

2026-10-23 17:37:00 UTC#508290duplicateconfirmednews

Roche and Ionis report Phase 3 IMAgINATION study data for sefaxersen in IgA nephropathy

yahooimportance 0.30trust 0.80Ionis Pharmaceuticals, Inc. +0.40Roche Holding AG +0.50sefaxersen +0.50+1 entities

2026-10-23 17:37:00 UTC#508242duplicateconfirmednews

Ionis Pharmaceuticals reports Roche's sefaxersen met primary endpoint in Phase 3 IgA nephropathy study

tradingviewimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. +0.60Roche Holding AG +0.60sefaxersen +0.60+1 entities

2026-10-22 09:45:00 UTC#498815duplicateconfirmednews

BMO Capital upgrades Ionis Pharmaceuticals to Outperform, raises price target to $66

dow_jonesimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. +0.50BMO Capital Markets Corp. +0.50

2026-10-21 21:21:29 UTC#496019newconfirmednews

Ionis Pharmaceuticals upgraded at BMO Capital Markets on positive Tryngolza adoption outlook

seeking alphaimportance 0.40trust 0.70Ionis Pharmaceuticals, Inc. +0.50BMO Capital Markets 0Tryngolza +0.50

2026-10-20 20:19:06 UTC#489012duplicateconfirmednews

FDA approves GSK's Hibsago for chronic hepatitis B, targeting over £2 billion in peak annual sales

reutersimportance 0.40trust 0.90GSK plc +0.60Hibsago +0.60Ionis Pharmaceuticals, Inc. +0.40+2 entities

2026-10-16 11:12:00 UTC#471436duplicateconfirmednews

Ionis Pharmaceuticals' Tryngolza receives positive CHMP opinion for severe hypertriglyceridemia

dow_jonesimportance 0.30trust 0.90Ionis Pharmaceuticals, Inc. +0.50Tryngolza +0.50European Medicines Agency +0.30+2 entities

2026-10-16 10:45:00 UTC#471299newconfirmednews

Ionis Pharmaceuticals' TRYNGOLZA receives positive CHMP opinion for severe hypertriglyceridemia in EU

tradingviewimportance 0.70trust 0.80Ionis Pharmaceuticals, Inc. +0.70TRYNGOLZA +0.70European Medicines Agency +0.60+1 entities

2026-09-24 11:09:00 UTC#361817newconfirmednews

H.C. Wainwright maintains $100 price target on Ionis Pharmaceuticals (IONS)

dow_jonesimportance 0.30trust 0.60Ionis Pharmaceuticals, Inc. 0H.C. Wainwright & Co. 0

2026-09-23 16:13:00 UTC#357071duplicateconfirmednews

Ionis Pharmaceuticals confirms positive Phase 3 FUSION study results for ulefnersen in FUS-ALS treatment

yahooimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. +0.50ulefnersen +0.50FUSION +0.40+2 entities

2026-09-23 05:00:00 UTC#353200duplicateconfirmednews

Ionis Pharmaceuticals reports positive Phase 3 interim results for sefaxersen in IgA nephropathy study

tradingviewimportance 0.60trust 0.80Ionis Pharmaceuticals, Inc. +0.60Roche Holding AG +0.60sefaxersen +0.60+2 entities

2026-09-22 13:29:34 UTC#349172duplicateconfirmednews

Ionis Pharmaceuticals shares rise following positive Phase 3 trial results for ulefnersen in ALS

seeking alphaimportance 0.30trust 0.60Ionis Pharmaceuticals, Inc. +0.50ulefnersen +0.50Amyotrophic Lateral Sclerosis 0

2026-09-22 13:00:08 UTC#348895duplicateconfirmedpress release

Ionis Pharmaceuticals reports positive Phase 3 Fusion study results for Ulefnersen in FUS-ALS treatment

reutersimportance 0.50trust 0.90Ionis Pharmaceuticals, Inc. +0.70Ulefnersen +0.70FUS-ALS +0.70+1 entities

2026-09-22 12:38:34 UTC#348741newconfirmednews

Otsuka and Ionis report experimental ALS drug meets primary endpoint in late-stage clinical trial

reutersimportance 0.60trust 0.90Otsuka Pharmaceutical Co., Ltd. +0.60Ionis Pharmaceuticals, Inc. +0.60

2026-09-22 12:33:00 UTC#348692newconfirmednews

JPMorgan cuts Ionis Pharmaceuticals (IONS) price target to $70 from $76, maintains Overweight

dow_jonesimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. -0.30JPMorgan Chase & Co. -0.30

2026-09-16 12:42:52 UTC#320702newconfirmednews

Ionis Pharmaceuticals (IONS) reports growth momentum driven by TRYNGOLZA and ZANVASTRO launches

quartrimportance 0.40trust 0.50Ionis Pharmaceuticals, Inc. +0.50TRYNGOLZA +0.50ZANVASTRO +0.50+1 entities

2026-09-15 13:31:00 UTC#314164newconfirmednews

Guggenheim cuts Ionis Pharmaceuticals (IONS) price target to $80 from $89

dow_jonesimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. -0.30Guggenheim Partners, LLC -0.30

2026-09-10 13:46:29 UTC#292584newconfirmednews

Ionis Pharmaceuticals (IONS) reports strong TRYNGALZA and DAWNZERA sales, advances HBV and IgA pipeline

quartrimportance 0.40trust 0.50Ionis Pharmaceuticals, Inc. +0.60TRYNGALZA +0.60DAWNZERA +0.60+1 entities

2026-09-08 14:27:00 UTC#281472newconfirmednews

Goldman Sachs maintains Neutral rating on Ionis Pharmaceuticals (IONS)

dow_jonesimportance 0.30trust 0.70Ionis Pharmaceuticals, Inc. 0The Goldman Sachs Group, Inc. 0

2026-09-08 11:28:00 UTC#280170newconfirmednews

H.C. Wainwright cuts Ionis Pharmaceuticals (IONS) price target to $100 from $115, maintains Buy

dow_jonesimportance 0.40trust 0.70Ionis Pharmaceuticals, Inc. -0.30H.C. Wainwright & Co., LLC -0.20